Phase III long-term safety study of SJP-0135 in patients with primary open-angle glaucoma or ocular hypertensio
- Conditions
- Primary open-angle glaucoma (broad definition) or ocular hypertension
- Registration Number
- JPRN-UMIN000026471
- Lead Sponsor
- Senju Pharmaceutical co.,ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 125
Not provided
1) History of surgical intervention or laser treatment for glaucoma 2) History of intraocular surgery 3) Presence of any circulatory failure such as cerebrovascular disease, orthostatic hypotension, cardiovascular disease and not eligible in the opinion of the investigator or the sub-investigator 4) Presence or history of bronchial asthma, bronchospasm or serious chronic obstructive pulmonary disease 5) Presence or history of uncontrolled heart failure, sinus bradycardia, atrioventricular block (Grade II or III) or cardiogenic shock 6) Presence of right heart failure caused by pulmonary hypertension, congestive heart failure, diabetic ketoacidosis, metabolic acidosis or uncontrolled diabetes mellitus 7) Serious visual field defect 8) History of corneal transplantation or keratorefractive surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method